Santen releases long-term data on PRESERFLO® MicroShunt and Endothelial Cell Density loss

June 29, 2023

Article

The pharmaceutical company will present study results at the World Glaucoma Congress.

An auditorium full of people in a lecture hall, paying attention to an on-stage presentation. Image credit: ©Gennady Danilkin – stock.adobe.com

Santen will present data on 2-year and 4-year outcomes, as well as figures from a 3-year cohort. Image credit: ©Gennady Danilkin – stock.adobe.com

In a news release, ophthalmology specialist Santen previewed long-term data on the PRESERFLO® MicroShunt.¹ The data will be presented in poster format at the World Glaucoma Congress (WGC), held in Rome, Italy, from 28 June to 1 July. Santen, headquartered in Osaka, Japan, will also host two symposia at the WGC.

According to the news release, data from an ongoing Open-Label Extension Study on PRESERFLO® MicroShunt (INN005) reflects 4-year outcomes in Endothelial Cell Density (ECD) loss.¹ “The risk of Endothelial Cell Density (ECD) loss has long been a concern of surgeons implanting glaucoma stents,” said Professor Henny Beckers, University Eye Clinic, Maastricht, Netherlands. “This data 4 years on from PRESERFLO® MicroShunt surgery is reassuring for both surgeons and patients about the longer-term implications of their treatment.”¹

Data shared ahead of the WGC shows that “ECD loss at 4 years post-implantation is similar in patients implanted with PRESERFLO® MicroShunt and those who received trabeculectomy.” At month 48, “the mean percentage ECD loss from screening was -16.2 and -13.9, respectively (p=0.498).”¹ Santen’s posters will display data from an ongoing study with 4-year data points (P-437), as well as 2-year data from the INN005 study (P-433).

Further, Professor Ike Ahmed, Department of Ophthalmology, John A. Moran Eye Center, University of Utah, will share findings from a recently-published study. Professor Ahmed’s presentation will include 3-year retrospective data from “a large cohort of PRESERFLO® MicroShunt patients with mitomycin C (MMC) (n=135).” The news release indicates 59.4% of patients in that group were medication-free after three years.¹

Ioana Grobeiu, Head of Medical Affairs at Santen, said, “We are delighted to bring clinicians up to date on the latest evidence for our therapies through a range of symposia and poster presentations and to discuss the implications for patient care.”